抗IL-1治疗秋水仙碱抵抗性儿童FMF:HELIOS登记真实世界数据
抗IL-1治疗降低CRP水平及发作次数与严重程度,主要不良反应为局部皮肤反应和血细胞减少,无恶性肿瘤或严重不良反应,并首次报告按需使用抗IL-1。
要点
- 抗IL-1治疗可降低儿童秋水仙碱抵抗性FMF患者的CRP水平及发作次数与严重程度
- 阿那白滞素与卡那奴单抗在儿童FMF中有效且安全,无恶性肿瘤或严重不良反应
- 首次报告按需使用抗IL-1治疗儿童FMF患者
核心结论
- 阿那白滞素和卡那奴单抗是秋水仙碱抵抗或不耐受儿童FMF患者有效且安全的替代选择。
研究设计与样本
- HELIOS为基于网络的儿童风湿病生物制剂登记,分析接受抗IL-1治疗的FMF患者的临床特征、疾病活动参数、治疗反应及安全性。
主要发现
- 持续治疗组(女性占61.7%)开始秋水仙碱治疗的平均年龄为5.55(3.87)岁。
- 开始抗IL-1治疗的平均年龄为11.47(5.41)岁,平均随访时间为3.87(1.96)年。
- 除2例外,所有患者均携带双等位基因外显子10突变。
- 抗IL-1治疗降低了CRP水平及发作次数与严重程度。
- 末次访视时,6例使用阿那白滞素、28例使用卡那奴单抗。
关键数值与推荐
- 阿那白滞素作为一线抗IL-1治疗。
- 3例因轻度感染住院;11例出现局部皮肤反应;2例使用阿那白滞素后出现白细胞减少;1例使用卡那奴单抗后出现血小板减少。
- 无恶性肿瘤或其他严重不良反应报告。
临床怎么用
- 对秋水仙碱抵抗或不耐受的儿童FMF患者,可选用阿那白滞素或卡那奴单抗抗IL-1治疗。
- 治疗中需监测局部皮肤反应及血细胞减少等不良反应。
- 按需使用抗IL-1为儿童FMF提供新的治疗模式,但需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: FMF is a prototype of autoinflammatory diseases associated with excess IL1 production. Anti-IL1 treatments are the first-line alternatives in colchicine-resistant/intolerant FMF patients. We aimed to investigate the efficacy and safety of anti-IL1 treatment in paediatric FMF patients in our local [Hacettepe univErsity eLectronIc research fOrmS (HELIOS)] registry. METHODS: HELIOS is a web-based biologic drug registry for paediatric rheumatology patients. We have analysed the clinical features, disease activity parameters, treatment responses and safety outcomes in FMF patients treated with anti-IL1 agents. RESULTS: Forty paediatric FMF patients (34 continuous and six on-demand use) were included. Among the continuously treated group (61.7% female), the mean age at the start of colchicine was 5.55 (3.87) years. Age at onset of the anti-IL1 treatment was 11.47 (5.41) years with a mean follow-up duration of 3.87 (1.96) years. Apart from two, all patients had biallelic exon-10 mutations. We also gave anti-IL1 treatment on an on-demand basis in six patients. Anakinra was used as the first-line anti-IL1 treatment. During the last visit, six patients were treated with anakinra and 28 patients with canakinumab. Anti-IL1 treatment decreased the CRP levels and number and severity of the attacks. There were three hospitalizations reported due to mild infections. Eleven patients had local skin reactions, two patients had leucopenia with anakinra and one patient had thrombocytopenia with canakinumab. There was no malignancy or other severe adverse reactions. CONCLUSION: Anakinra and canakinumab are efficient and safe alternatives in colchicine-resistant or -intolerant paediatric FMF patients. We also, for the first time, report on-demand use of anti-IL1 in paediatric FMF patients.
引用
- Sag E, Akal F, Atalay E, et al. Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry. Rheumatology (Oxford). 2020. PMID: 32306038. doi:10.1093/rheumatology/keaa121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。